Abstract

Hyperthyroidism triggers a glycolytic shift in skeletal muscle (SKM) by altering the expression of metabolic proteins, which is often accompanied by peripheral insulin resistance. Our previous results show that smoothelin-like protein 1 (SMTNL1), a transcriptional co-regulator, promotes insulin sensitivity in SKM. Our aim was to elucidate the role of SMTNL1 in SKM under physiological and pathological 3,3′,5-Triiodo-L-thyronine (T3) concentrations. Human hyper- and euthyroid SKM biopsies were used for microarray analysis and proteome profiler arrays. Expression of genes related to energy production, nucleic acid- and lipid metabolism was changed significantly in hyperthyroid samples. The phosphorylation levels and activity of AMPKα2 and JNK were increased by 15% and 23%, respectively, in the hyperthyroid samples compared to control. Moreover, SMTNL1 expression showed a 6-fold decrease in the hyperthyroid samples and in T3-treated C2C12 cells. Physiological and supraphysiological concentrations of T3 were applied on differentiated C2C12 cells upon SMTNL1 overexpression to assess the activity and expression level of the elements of thyroid hormone signaling, insulin signaling and glucose metabolism. Our results demonstrate that SMTNL1 selectively regulated TRα expression. Overexpression of SMTNL1 induced insulin sensitivity through the inhibition of JNK activity by 40% and hampered the non-genomic effects of T3 by decreasing the activity of ERK1/2 through PKCδ. SMTNL1 overexpression reduced IRS1 Ser307 and Ser612 phosphorylation by 52% and 53%, respectively, in hyperthyroid model to restore the normal responsiveness of glucose transport to insulin. SMTNL1 regulated glucose phosphorylation and balances glycolysis and glycogen synthesis via the downregulation of hexokinase II by 1.3-fold. Additionally, mitochondrial respiration and glycolysis were measured by SeaHorse analysis to determine cellular metabolic function/phenotype of our model system in real-time. T3 overload strongly increased the rate of acidification and a shift to glycolysis, while SMTNL1 overexpression antagonizes the T3 effects. These lines of evidence suggest that SMTNL1 potentially prevents hyperthyroidism-induced changes in SKM, and it holds great promise as a novel therapeutic target in insulin resistance.

Highlights

  • Hyperthyroidism is a pathological disorder in which excess thyroid hormone (TH) is produced and secreted by the thyroid gland [1]

  • We previously showed that smoothelin-like protein 1 (SMTNL1) regulates insulin signaling by promoting the gene expression of glucose transport molecule 4 (GLUT4) and insulin receptor substrate 1 (IRS1) in murine skeletal muscle

  • The signaling pathways identified by microarray analysis showed altered expression of genes involved in metabolism, development, and cytoskeletal function in skeletal muscle (SKM) upon the clinical manifestations of hyperthyroidism

Read more

Summary

Introduction

Hyperthyroidism is a pathological disorder in which excess thyroid hormone (TH) is produced and secreted by the thyroid gland [1]. Thyroid hormones are key regulators of metabolism and development and have diverse effects. Thyroxine (T4) is the main product of thyroid secretion. Thyroxine is deiodinated in peripheral tissues to produce 3,3′,5-Triiodo-L-thyronine (T3), the biologically active TH [2]. The biological effects of THs are mediated through the interaction of T3 with high-affinity thyroid receptors (TRs). TRs are ligand-dependent nuclear transcription factors that interact with thyroid-responsive elements (TREs) located in the promoter of T3-responsive genes [3]. Five different subtypes of TRs (a1, a2, b1, b2, and b3) are encoded by two genes, TRa (NR1A1) and TRb (NR1A2). All subtypes except TRa2 bind T3 [4, 5]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call